101 related articles for article (PubMed ID: 19373161)
1. Paclitaxel: friend or foe for systemic lupus erythematosus?
Pan HF; Wu GC; Li XP; Ye DQ
South Med J; 2009 May; 102(5):554-5. PubMed ID: 19373161
[No Abstract] [Full Text] [Related]
2. Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer.
Dasanu CA; Alexandrescu DT
South Med J; 2008 Nov; 101(11):1161-2. PubMed ID: 19088531
[TBL] [Abstract][Full Text] [Related]
3. [Experimental approach to the pathogenesis of systemic lupus erythematosus].
Lambert PH; Creighton D; Goodman R; Bankhurst A; Mischer PA
J Urol Nephrol (Paris); 1972 Dec; 78(12):973-80. PubMed ID: 4350279
[No Abstract] [Full Text] [Related]
4. Paclitaxel hypersensitivity revisited.
Essayan DM; Kagey-Sobotka A; Lichtenstein LM
J Clin Oncol; 1996 Mar; 14(3):1042. PubMed ID: 8622009
[No Abstract] [Full Text] [Related]
5. Paclitaxel-related hypersensitivity reactions and monitoring recommendations.
Myers JS
Clin J Oncol Nurs; 2002; 6(3):177-8. PubMed ID: 11998615
[No Abstract] [Full Text] [Related]
6. [Iatrogenic lupus: present status of the problem. II. Physiopathology of induced lupus].
Dorfmann H; Kahn MF; de Sèze S
Nouv Presse Med; 1972 Dec; 1(44):2967-70. PubMed ID: 4122263
[No Abstract] [Full Text] [Related]
7. Systemic lupus erythematosus--immunoregulatory therapies.
Miller ML; Steinberg AD
Clin Rheum Dis; 1983 Dec; 9(3):617-28. PubMed ID: 6360516
[No Abstract] [Full Text] [Related]
8. Systemic lupus erythematosus.
Goust JM; Tsokos G
Immunol Ser; 1993; 58():437-49. PubMed ID: 8424987
[No Abstract] [Full Text] [Related]
9. Elimination of frequent vital sign monitoring in patients receiving paclitaxel.
Thomas M
Oncol Nurs Forum; 1998 Jun; 25(5):828. PubMed ID: 9644696
[No Abstract] [Full Text] [Related]
10. The remarkable "paclitaxel story": how many chapters remain to be written?
Markman M
Gynecol Oncol; 2008 Oct; 111(1):7-8. PubMed ID: 18682311
[No Abstract] [Full Text] [Related]
11. Paclitaxel-induced acral erythema.
Richards KN; Ivan D; Rashid RM; Chon SY
Arch Dermatol; 2012 Nov; 148(11):1333-4. PubMed ID: 23165853
[No Abstract] [Full Text] [Related]
12. Paclitaxel induced systemic lupus erythematosus in a case of cervical carcinoma.
Sanghavi SA; Chikhalkar S; Khopkar US
Indian J Dermatol Venereol Leprol; 2013; 79(4):537-9. PubMed ID: 23760331
[No Abstract] [Full Text] [Related]
13. Acute gout during treatment with paclitaxel for metastatic melanoma.
Alexandrescu DT; Ichim TE; Kabigting F; Dasanu CA
Rheumatology (Oxford); 2009 Jul; 48(7):862-3. PubMed ID: 19458161
[No Abstract] [Full Text] [Related]
14. Paclitaxel-induced myocardial infarction in a case of carcinoma ovary.
Londhey VA; Parikh FS
J Assoc Physicians India; 2009 Apr; 57():342-3. PubMed ID: 19702043
[No Abstract] [Full Text] [Related]
15. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody.
Adachi A; Horikawa T
J Dermatol; 2007 Jul; 34(7):473-6. PubMed ID: 17584326
[TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
17. [Paclitaxel in therapy of breast carcinoma. Value and perspectives].
Klaassen U; Seeber S
Med Klin (Munich); 1996 Dec; 91 Suppl 2():7-10. PubMed ID: 9082172
[No Abstract] [Full Text] [Related]
18. [Taxol].
Kühnle H
Zentralbl Gynakol; 1996; 118(10):580. PubMed ID: 8999717
[No Abstract] [Full Text] [Related]
19. Association between paclitaxel and necrotic pancreatitis.
McMahon MA; Kearns G; McCaffrey J; Grogan L
Ir Med J; 2006 Oct; 99(9):281. PubMed ID: 17144240
[TBL] [Abstract][Full Text] [Related]
20. Safety profile of single-dose dexamethasone premedication for paclitaxel.
Parikh B; Khanolkar S; Advani SH; Dhabhar B; Chandra M
J Clin Oncol; 1996 Jul; 14(7):2189-90. PubMed ID: 8683256
[No Abstract] [Full Text] [Related]
[Next] [New Search]
